Elesclomol (STA-4783)

Name: Elesclomol (STA-4783)
Brand: Selleck Chemicals
SKU: S1052
Rating: 5 (9 reviews)

For research use only.

Catalog No.S1052

9 publications

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Selleck's Elesclomol (STA-4783) has been cited by 9 publications

Cell, 2017, 168(1-2):86-100

PubMed: 27916275 ( click the link to review the publication )

Nat Commun, 2020, 15;11(1):2423

PubMed: 32415069 ( click the link to review the publication )

EBioMedicine, 2020, 54:102715

PubMed: 32251998 ( click the link to review the publication )

Osteoporos Int, 2018, 29(8):1917-1926

PubMed: 29860665 ( click the link to review the publication )

Oncol Rep, 2018, 40(2):635-646

PubMed: 29917168 ( click the link to review the publication )

Int J Biochem Cell Biol, 2017, 85:166-174

PubMed: 28259749 ( click the link to review the publication )

Int J Radiat Biol, 2017, 93(2):194-203

PubMed: 27600766 ( click the link to review the publication )

Oncotarget, 2016, 10.18632/oncotarget.10921

PubMed: 27486766 ( click the link to review the publication )

BMC Genomics, 2014, 15(1):263

PubMed: 24708151 ( click the link to review the publication )

4 Customer Reviews

BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.
Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Targets

HSP70 ^[1]
(Cell-free assay)

In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. ^[1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. ^[2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NOS-1 cell	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NIHCVJNKdmirYnn0bY9vKG:oIHj1cYFvKE6RUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKDNwNk\lMVA2KM7:TR?=	MUfTRW5ITVJ?
CAL-51 cell	NULlXmk6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M1jzWWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOjZibl2=	M{jWO3NCVkeHUh?=
ABC-1 cell	NU\oTHFTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFe3ZYNKdmirYnn0bY9vKG:oIHj1cYFvKEGEQz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{PjVibl2=	MUfTRW5ITVJ?
A2780 cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MUXJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD61PVQhdk1?	MkPiV2FPT0WU
ES1 cell	M4Oyd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M{XtdGlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD63OFkhdk1?	NXLEZmVFW0GQR1XS
HUTU-80 cell	M4TFXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MlPDTY5pcWKrdHnvckBw\iCqdX3hckBJXVSXLUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44QTFibl2=	MULTRW5ITVJ?
NCI-H292 cell	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NHjWTZpKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OE[gcm0>	Mon6V2FPT0WU
NB69 cell	M2flbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M4DjeWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNlIhdk1?	M2\UOnNCVkeHUh?=
ES8 cell	NX60O2E3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M{XRfWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6zNkBvVQ>?	M{HQSnNCVkeHUh?=
BCPAP cell	MlLOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M2TrUGlvcGmkaYTpc44hd2ZiaIXtZY4hSkOSQWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlM1KG6P	MofaV2FPT0WU
T-24 cell	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NXvVXVRtUW6qaXLpeIlwdiCxZjDoeY1idiCWLUK0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42PSCwTR?=	NGnxPZNUSU6JRWK=
EW-16 cell	NILtbYVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MVfJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT62NUBvVQ>?	MXfTRW5ITVJ?
OVCAR-5 cell	M2DTS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MoLGTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OyCwTR?=	M2C4WHNCVkeHUh?=
SF126 cell	NIL3S4FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MkPSTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPVUhdk1?	NGjCfGFUSU6JRWK=
KP-4 cell	NGrxfZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M4XDZ2lvcGmkaYTpc44hd2ZiaIXtZY4hU1BvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNVchdk1?	NFvnVlNUSU6JRWK=
GAMG cell	NGTCSJhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWrJcohq[mm2aX;uJI9nKGi3bXHuJGdCVUdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWxJI5O	NX7BcHpvW0GQR1XS
HOS cell	MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MUfJcohq[mm2aX;uJI9nKGi3bXHuJGhQWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwNUOgcm0>	MXnTRW5ITVJ?
CHL-1 cell	M1;kd2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NIHrWFdKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk45OSCwTR?=	NV3tSVhUW0GQR1XS
AGS cell	MnP5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVrJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwOE[gcm0>	NGjRN\|hUSU6JRWK=
MDA-MB-157 cell	NGWycW1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NI\4[\|RKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0yPTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmyJI5O	NYjneVhyW0GQR1XS
HSC-3 cell	M3qxfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGD3W4JKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?=	Mn3LV2FPT0WU
CAL-72 cell	M1joW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1rTZ2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOiCwTR?=	M3njRXNCVkeHUh?=
NBsusSR cell	MmTES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MXLJcohq[mm2aX;uJI9nKGi3bXHuJG5De3W\|U2KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlE{KG6P	NUjuPIdVW0GQR1XS
ES7 cell	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2XzNmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz61PUBvVQ>?	M4HrWnNCVkeHUh?=
H-EMC-SS cell	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NFTL[W1KdmirYnn0bY9vKG:oIHj1cYFvKEhvRV3DMXNUKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54ODDuUS=>	M4HYPXNCVkeHUh?=
NCI-H1703 cell	MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUewN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPjhibl2=	MVzTRW5ITVJ?
BHT-101 cell	NX;QfnpvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NW\JeG51UW6qaXLpeIlwdiCxZjDoeY1idiCESGStNVAyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy55MjDuUS=>	NVH4[41bW0GQR1XS
SK-OV-3 cell	MlrqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mn2zTY5pcWKrdHnvckBw\iCqdX3hckBUUy2RVj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44PSCwTR?=	NXG1bWVDW0GQR1XS
EW-24 cell	M1jy[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MnXqTY5pcWKrdHnvckBw\iCqdX3hckBGXy1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuPFMhdk1?	M3XlT3NCVkeHUh?=
PSN1 cell	NUfRNHc2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NGOxdG9KdmirYnn0bY9vKG:oIHj1cYFvKFCVTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlg1KG6P	MUTTRW5ITVJ?
OVCAR-8 cell	MlP3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M{\HWGlvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQTlibl2=	NEPrOJpUSU6JRWK=
NCI-H1563 cell	M{i4Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MUnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW2N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTNibl2=	NX7QWIdzW0GQR1XS
SW756 cell	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NELUcW9KdmirYnn0bY9vKG:oIHj1cYFvKFOZN{W2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4yOyCwTR?=	MXzTRW5ITVJ?
A375 cell	NEPiOYhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M{TNd2lvcGmkaYTpc44hd2ZiaIXtZY4hSTN5NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNVQhdk1?	M4n2OnNCVkeHUh?=
Ca9-22 cell	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MofrTY5pcWKrdHnvckBw\iCqdX3hckBE[TlvMkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlI2KG6P	MnPkV2FPT0WU
SW1990 cell	NVHlVVZDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MmDITY5pcWKrdHnvckBw\iCqdX3hckBUXzF7OUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlMzKG6P	MVfTRW5ITVJ?
ES4 cell	NWW0N2VnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXXERXBIUW6qaXLpeIlwdiCxZjDoeY1idiCHU{SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlM6KG6P	NHHJN\|lUSU6JRWK=
HCE-T cell	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NXTEPWNqUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPDVibl2=	M1S4S3NCVkeHUh?=
MOLT-16 cell	MnXkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3G5[GlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvPTNibl2=	NFrP[o9USU6JRWK=
HSC-4 cell	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NV\WOHdmUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQCCwTR?=	NWG5V2NDW0GQR1XS
NCI-SNU-1 cell	NVn3V3B1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MXHJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2VTmWtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQDZibl2=	M1HGc3NCVkeHUh?=
EW-11 cell	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1W2NGlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlkhdk1?	M13zdnNCVkeHUh?=
HT-1080 cell	NEnFbmJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NFPCSVVKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7IH7N	MXHTRW5ITVJ?
MES-SA/Dx5 cells	NIfpco1EgXSxdH;4bYNqfHliYYPzZZk>	MnvhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWVUNVODL1T4OUBk\WyuczygTWM2OD13IH7N	NY\VV2d3OjN7M{e5PFE>
SW1710 cell	NYLmd2N6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NHviUGVKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOTZibl2=	NGTRRXBUSU6JRWK=
EW-1 cell	Mn7jS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mn\OTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT6yOEBvVQ>?	Mm[yV2FPT0WU
BV-173 cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MlvCTY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6KG6P	MUfTRW5ITVJ?
TE-8 cell	M1TpcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NEjnRWZKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQyKG6P	NUfVTINZW0GQR1XS
G-401 cell	M13oSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MmjhTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuOFMhdk1?	MVHTRW5ITVJ?
KOSC-2 cell	MnKxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3fT[WlvcGmkaYTpc44hd2ZiaIXtZY4hU0:VQz2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41PSCwTR?=	NHr6[phUSU6JRWK=
HuCCT1 cell	NFTodXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NIPmNFZKdmirYnn0bY9vKG:oIHj1cYFvKEi3Q1PUNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTJibl2=	MWDTRW5ITVJ?
FADU cell	MlTYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYPJcohq[mm2aX;uJI9nKGi3bXHuJGZCTFViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lk[2JI5O	Mn;VV2FPT0WU
MHH-ES-1 cell	NEGyOGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MWPJcohq[mm2aX;uJI9nKGi3bXHuJG1JUC2HUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43QSCwTR?=	NYfLUGlWW0GQR1XS
ES3 cell	MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M2f6RmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT63PUBvVQ>?	M1fz[XNCVkeHUh?=
OVCAR-4 cell	MmTWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NWf1[VlrUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NzDuUS=>	MnjDV2FPT0WU
HD-MY-Z cell	NYP4[ZNGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mk[5TY5pcWKrdHnvckBw\iCqdX3hckBJTC2PWT3aJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46OSCwTR?=	MY\TRW5ITVJ?
human JAR cell	NHzkXIlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NVPkR\|ZCUW6qaXLpeIlwdiCxZjDoeY1idiCMQWKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk4KG6P	Mli2V2FPT0WU
A427 cell	NYfFSFFST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M3HTXWlvcGmkaYTpc44hd2ZiaIXtZY4hSTR{NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNFchdk1?	MlfaV2FPT0WU
697 cell	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MYTJcohq[mm2aX;uJI9nKGi3bXHuJFY6PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTZwMUOgcm0>	MoflV2FPT0WU
OVCAR-3 cell	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NV;BWlBSUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5{IH7N	NUXudYhVW0GQR1XS
human NB14 cell	NFXzd5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MX7Jcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14Lk[0JI5O	MkDUV2FPT0WU
GB-1 cell	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MoLuTY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nj63NUBvVQ>?	NHPMW\|RUSU6JRWK=
COR-L105 cell	NWnGeYUxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M4\yZmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyxNFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03Njd4IH7N	NYPLdlR1W0GQR1XS
647-V cell	MnHuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NFXrXotKdmirYnn0bY9vKG:oIHj1cYFvKDZ2Nz3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok46KG6P	MVPTRW5ITVJ?
human K5 cell	NF\QV5dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NUjWdHdRUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUegcm0>	MonYV2FPT0WU
DMS-273 cell	NXjudm9VT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Mnu4TY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?=	MoLuV2FPT0WU
UM-UC-3 cell	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MWnJcohq[mm2aX;uJI9nKGi3bXHuJHVONVWFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA3KG6P	M4TV[HNCVkeHUh?=
HEL cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NVLPNI0{UW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlA5KG6P	Mmr6V2FPT0WU
human KU-19-19 cell	NETUfmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NWPoZ5F4UW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdwMEmgcm0>	MVHTRW5ITVJ?
MC-IXC cell	NYfm[oJiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M3m2bGlvcGmkaYTpc44hd2ZiaIXtZY4hVUNvSWjDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4yPyCwTR?=	MYHTRW5ITVJ?
human H4 cell	NGDwV\|lIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MkLRTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTdwMkWgcm0>	MkToV2FPT0WU
NUGC-3 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M3jnTmlvcGmkaYTpc44hd2ZiaIXtZY4hVlWJQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{OyCwTR?=	M4C5PXNCVkeHUh?=
CHP-212 cell	NEDlTFVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXnJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlM1KG6P	M2W5[XNCVkeHUh?=
human SW982 cell	NXLUZ3dGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NH3MZmVKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41PCCwTR?=	NX\qS4J{W0GQR1XS
C-33-A cell	MkLmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NUXUPHZNUW6qaXLpeIlwdiCxZjDoeY1idiCFLUOzMWEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV6IH7N	MoLJV2FPT0WU
PC-3 cell	M2TZPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MnrQTY5pcWKrdHnvckBw\iCqdX3hckBRSy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Nz64PUBvVQ>?	M2K5e3NCVkeHUh?=
COLO-684 cell	NHXKOoZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	Ml7rTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOjFibl2=	M4SzW3NCVkeHUh?=
SNU-387 cell	M2jGNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mm\TTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvM{i3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU41QSCwTR?=	NFT6SY5USU6JRWK=
U251 cell	NY\r[I9oT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MVzJcohq[mm2aX;uJI9nKGi3bXHuJHUzPTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17Lki2JI5O	MUDTRW5ITVJ?
A673 cell	NEfwXnhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NEjGdohKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU43KG6P	NGrITYRUSU6JRWK=
human T47D cell	M164bmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MkjvTY5pcWKrdHnvckBw\iCqdX3hckBVPDeGIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MU[uO\|khdk1?	NVnjdVVOW0GQR1XS
A549 cell	M1LMbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zOT62JI5O	MVrTRW5ITVJ?
PC-14 cell	NWXpZlhJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M3\sT2lvcGmkaYTpc44hd2ZiaIXtZY4hWENvMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOE44OyCwTR?=	Mm\yV2FPT0WU
A704 cell	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXrJcohq[mm2aX;uJI9nKGi3bXHuJGE4ODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Nz60OUBvVQ>?	NGDjTFJUSU6JRWK=
MCF7 cell	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	Mn\uTY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;M{GuN\|Yhdk1?	NWrIPZhPW0GQR1XS
PC3 cells	M136dmZ2dmO2aX;uJIF{e2G7	MnezTY5pcWKrdHnvckBw\iCSRFuxMY1m\GmjdHXkJGFMXCCyaH;zdIhwenmuYYTpc44h[XRiVHjyN\|A5KHKnc3nkeYUhcW5iaIXtZY4hWEN\|IHPlcIx{KGK7IFXMTXNCNCCLQ{WwQVAvOTF\|IN88US=>	MYqyNVM1OTZ5NR?=
F-36P cells	MoXkVJJwdGmoZYLheIlwdiCjc4PhfS=>	M{nvXWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRj2zOnAh[2WubIOsJGlEPTB;MD6yPEDPxE1?	MVuyNVM1OTZ5NR?=
OCI-AML2 cells	NYLZ[I9FWHKxbHnm[ZJifGmxbjDhd5NigQ>?	NGXRNWpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;DTU1CVUx{IHPlcIx{NCCLQ{WwQVAvOzVizszN	NE[1VnkzOTN2MU[3OS=>
K562 cells	M2\MUXBzd2yrZnXyZZRqd25iYYPzZZk>	M2XEdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS{W2NkBk\WyuczygTWM2OD1zODFOwG0>	NGK5ZoszOTN2MU[3OS=>

... Click to View More Cell Line Experimental Data

In vivo

Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. ^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: Hs294T, HSB2, and Ramos
Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
Incubation Time: 18, or 24 hours
Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
(Only for Reference)

Animal Research:^[4]

- Collapse

Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
Dosages: ~100 mg/kg
Administration: Intravenous injection
(Only for Reference)

References

[4] Gehrmann M. Curr Opin Investig Drugs, 2006, 7(6), 574-580.

- Collapse

Solubility (25°C)

In vitro	DMSO	80 mg/mL (199.75 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40%PEG300+5%Tween80 +50%H2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Elesclomol (STA-4783) SDF

Molecular Weight	400.5
Formula	C₁₉H₂₀N₄O₂S₂
CAS No.	488832-69-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(NC(=O)CC(=O)NN(C)C(=S)C1=CC=CC=C1)C(=S)C2=CC=CC=C2

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can we use the compound for in vivo mouse studies?
Answer:
S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Tanespimycin (17-AAG)

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 2.

Features:Displays very low toxicity toward normal cells.
Luminespib (NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth inhibition, autophagy and apoptosis. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM. NVP-HSP990 induces cell cycle arrest and apoptosis.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Elesclomol (STA-4783)